Review Addresses Rituxan and Bendamustine as First-line Treatment for CAD
News
First-line treatment of cold agglutinin disease (CAD) should employ a combination of Rituxan (rituximab) and bendamustine, according to a review study. The scientists also highlight the potential of therapies targeting ... Read more